Cabaletta Bio Stock Today
| CABA Stock | USD 3.82 0.81 26.91% |
Performance0 of 100
| Odds Of DistressLess than 11
|
Cabaletta Bio is trading at 3.82 as of the 30th of November 2024, a 26.91 percent increase since the beginning of the trading day. The stock's open price was 3.01. Cabaletta Bio has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Cabaletta Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of October 2019 | Category Healthcare | Classification Health Care |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. The company has 48.88 M outstanding shares of which 3.6 M shares are currently shorted by private and institutional investors with about 4.26 trading days to cover. More on Cabaletta Bio
Moving against Cabaletta Stock
Cabaletta Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Technology | Gwendolyn Binder | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCabaletta Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cabaletta Bio's financial leverage. It provides some insight into what part of Cabaletta Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cabaletta Bio (CABA) is traded on NASDAQ Exchange in USA. It is located in 2929 Arch Street, Philadelphia, PA, United States, 19104 and employs 136 people. Cabaletta Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 186.71 M. Cabaletta Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 48.88 M outstanding shares of which 3.6 M shares are currently shorted by private and institutional investors with about 4.26 trading days to cover.
Cabaletta Bio currently holds about 96.81 M in cash with (53.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34.
Check Cabaletta Bio Probability Of Bankruptcy
Ownership AllocationThe majority of Cabaletta Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cabaletta Bio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cabaletta Bio. Please pay attention to any change in the institutional holdings of Cabaletta Bio as this could imply that something significant has changed or is about to change at the company.
Check Cabaletta Ownership Details
Cabaletta Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sofinnova Ventures | 2024-06-30 | 1.2 M | |
| Commodore Capital Lp | 2024-09-30 | 1.1 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.1 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 956.7 K | |
| Millennium Management Llc | 2024-06-30 | 698.3 K | |
| Point72 Asset Management, L.p. | 2024-09-30 | 667.3 K | |
| Victory Capital Management Inc. | 2024-09-30 | 629.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 591 K | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 582.3 K | |
| Jennison Associates Llc | 2024-09-30 | 5.6 M | |
| Blackrock Inc | 2024-06-30 | 4.8 M |
Cabaletta Bio Historical Income Statement
Cabaletta Stock Against Markets
Cabaletta Bio Corporate Management
| Samik MD | Chief Officer | Profile | |
| Steven MD | Chairman, CoFounder | Profile | |
| FACR MD | Chief Officer | Profile | |
| Michael JD | General Secretary | Profile | |
| Heather MSc | Chief Officer | Profile | |
| Qing Yuan | Chief Officer | Profile | |
| Aimee MD | CoFounder Board | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Return On Assets (0.31) | Return On Equity (0.48) |
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.